NCT05193565 - Study to Compare the Efficacy and Safety After Conversion to RaparoBell® or My-Rept® in Kidney Transplant Patients | Biotech Hunter

Enrollment

206

Participants

Timeline

Start Date

November 19, 2021

Primary Completion Date

January 31, 2024

Study Completion Date

June 30, 2024

Conditions

Kidney Transplantation

Interventions

DRUG

Sirolimus

Orally, once-daily in the morning - Check the blood concentration of Sirolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 3\~8ng/mL

DRUG

Mycophenolate mofetil

Up to 1g BID(total 2g daily), PO

Trial Locations (1)

Unknown

RECRUITING

The Catholic University of Korea, Seoul, St.Mary's Hospital, Seoul